FDA Approved: BIVALIRUDIN — Supplemental Application (Fresenius Kabi USA, LLC)

View source ↗

Summary

The FDA approved a supplemental application for the generic anticoagulant Bivalirudin from Fresenius Kabi USA, LLC.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease
• Coronary Syndrome
• Myocardial Infarction

Drugs mentioned

• Bivalirudin (bivalirudin)

Snippet

SUPPL AP for BIVALIRUDIN (BIVALIRUDIN)